Identification of a RNA-Seq based signature to improve prognostic for uterine sarcoma

abstracts

Annals of Oncology 1046P

Identification of a RNA-Seq based signature to improve prognostic for uterine sarcoma

J-G. Zhou, H. Ma Department of Oncology, Zunyi Medical University Affiliated Hospital, Zunyi, China

1047P

The effect of multiple interventions for women at risk for cervical cancer on their health responsibility, beliefs regarding cervical cancer, and having screening: A randomized controlled experiment

B. Altinel, B. Akin Public Health, Selcuk University, Konya, Turkey Background: This study is a pretest-posttest, randomized, controlled experimental study that was intended to analyze the effect of multiple initiatives on beliefs about cervical cancer, health responsibility, and screening participation. Methods: The group that was addressed were women between 40 and 55 years of age who were at risk of cervical cancer. The study was carried out between March 13 and June 18, 2017 in a primary health care center. The sample for this study included 134 women (experimental group: 64; control group; 67). The 14 weeks of sessions involving the experimental group included group training and delivery of brochures on cervical cancer, training and counseling during home visits, reminder phone calls, and delivery of materials, all aimed to increase motivation to be screened regularly for cervical cancer. The control group maintained their routine practices. To prevent any ethical violations, the group training as well as the brochures, magnets, and mugs that were given to the experimental group before the sessions were provided after the post-tests to the control group as well. The study data were collected using an information form, the Cervical Cancer and Pap-Smear Test Health Belief Model Scale, the Healthy Lifestyle Behaviors Scale II (Health Responsibility), and The Assessment Form for Undergoing Pap-Smear Test. The data were analyzed using dependent groups t test and independent groups t test. Results: After the multiple interventions, there was a significant difference between the test and control groups’ Health Responsibility, Pap smear benefit and motivation, Pap smear obstacle and health motivation scores (p < 0.05). After multiple interventions, the participation rate of women in the experimental group to cervical cancer screening was found to be 93% and the rate of cervical cancer screening was significantly higher than in the control group (p < 0.05). Conclusions: In the light of the results of these studies, it may be suggested to conduct studies in factorial design where the effectiveness of different methods to increase participation in cervical cancer screening is evaluated. Clinical trial identification: NCT03076879, 26 September 2017. Legal entity responsible for the study: Busra Altinel. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

Volume 30 | Supplement 5 | October 2019

Quantifying the effects of the Korean national cancer screening program on cervical cancer mortality

N.C. Bui1, E. Choi1, M. Suh1, K-W. Jung2, J.K. Jun1, K.S. Choi1 Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si, Republic of Korea, 2Cancer Registration and Surveillance, National Cancer Center, Goyang-si, Republic of Korea

1

Background: Organized cervical cancer screening program for women aged 30 or over using Pap Smear has been launched in Korea since 1999. However, there is limited evidence showing the effectiveness of this nationwide screening program in reducing cervical cancer mortality. In this study, we aim to examine cervical cancer mortality among screened and non-screened women who participated in the Korean National Cancer Screening Program (KNCSP) from 2002 to 2003. Methods: We conducted a prospective cohort study of women aged 30-79 years invited to the KNCSP between 2002 - 2003 and followed up to 2015 for deaths from cervical cancer and other causes. Women with incomplete ID, diagnosed with cervical cancer before entering the cohort, or older than 79 years were excluded. Finally, a total of 8,262,267 women aged 30-79 were included, and their cervical cancer screening exposure, cancer incidence, and death information were collected from the KNCSP database, National Cancer Registry, and death certificate from Statistics Korea. There were 6,615,614 women in the screen group (mean person-year: 9.74) and 5,814,989 women in the non-screen group (mean person-year: 8.33). Incidence rate ratio (IRR) and Mortality rate ratio (MRR) were used to compare between screen and non-screen cohorts using Poisson regression model. The MRRs and IRRs were adjusted for age at inclusion in the cohort, insurance type, and self-selection bias. Results: The crude mortality rate was 3.49 and 8.77 per 100,000 women-years for screen and non-screen group, respectively. MRR for cervical cancer was 0.46 (95% confidence interval (CI): 0.44-0.48). After adjusting for self-selection bias, it was estimated that there was 36.11% of mortality reduction in screen group compared to non-screen group. Also, IRR of invasive cancer in screen group was 0.74 (95% CI: 0.72-0.76) compared to non-screen group. However, there was no significant reduction in the total number of invasive cervical cancer and cervical cancer in situ incidence rate (IRR: 0.98; 95%CI: 0.98 (0.96-1.00)). Conclusions: We found that after 13 years of follow-up, 36.11% of cervical cancer mortality reduction was observed among women who attended the Korean National Cervical Cancer Screening Program. Legal entity responsible for the study: Kui Son Choi. Funding: National Cancer Center, Korea (Grant number: 1610401) and International Cooperation & Education Program (NCCRINCCI 52210-52211,2019) of National Cancer Center, Korea. Disclosure: All authors have declared no conflicts of interest.

1049P

Spread of tumour and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumour diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis

T. Arimoto1, K. Takahiro2, T. Toita3, H. Kobayashi4, R. Machida5, T. Mizutani5, T. Onda6, M. Mizuno7, H. Yokota8, S. Kamiura9, K. Takehara10, H. Takano11, T. Saito12, M. Mandai13, T. Satoh14, S. Yamaguchi15, T. Nakamura16, K. Ushijima17, D. Aoki18, N. Yaegashi19 1 Obstetrics and Gynaecology, Toranomon Hospital, Minato-ku, Japan, 2Obstetrics & Gynecology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 3Radiology, Okinawa Chubu Hospital, Uruma, Japan, 4Obstetrics & Gynecology, Kagoshima University Hospital, Kagoshima, Japan, 5Clinical Research Support Office, National Cancer Center Hospital, Chuo-ku, Japan, 6Obstetrics & Gynecology, Kitasato University Hospital, Sagamihara, Japan, 7Gynaecology, Aichi Cancer Center hospital, Aichi, Japan, 8 Gynaecology, Saitama Cancer Center Hospital, Saitama, Japan, 9Gynaecology, Osaka International Cancer Institute, Osaka, Japan, 10Gynaecology, Shikoku Cancer Center, Ehime, Japan, 11Obstetrics and Gynaecology, The Jikei University Kashiwa Hospital, Kashiwa, Japan, 12Gynaecology, Kyushu Cancer Center, Fukuoka, Japan, 13Obstetrics and Gynaecology, Kyoto University Hospital, Kyoto, Japan, 14Obstetrics and Gynaecology, University of Tsukuba Hospital, Tsukuba, Japan, 15Gynaecology, Hyogo Cancer Center, Akashi, Japan, 16Obstetrics and Gynaecology, Kagoshima City Hospital, Kagoshima, Japan, 17Obstetrics and Gynaecology, Kurume University Hospital, Kurume, Japan, 18Obstetrics and Gynaecology, Keio University Hospital, Shinjuku-ku, Japan, 19 Obstetrics and Gynaecology, Tohoku University Hospital, Sendai, Japan Background: A single-arm confirmatory trial (JCOG1101) is now on follow-up, which is to evaluate the efficacy of modified radical hysterectomy for FIGO Stage IB1 uterine cervical cancer patients (pts) with clinical maximal tumor diameter (MTD) estimated 2 cm or less (UMIN-CTR: UMIN000009726). It is needed to evaluate whether application of modified radical hysterectomy is feasible or not. Methods: From Jan 2013 to Aug 2017, 240 pts were enrolled. We analyzed the data of 224 eligible pts who underwent modified radical hysterectomy to elucidate the relationship between clinical maximal tumor diameter (cMTD) and pathological MTD (pMTD), degree of tumor extension and adverse events (AEs). Results: In 224 eligible pts, median pMTD was 1.5 cm (range, 0-4.5), and. pMTD were< ¼ 2cm in 184 pts (82.1%). Parametrial involvement and lymph node metastasis were

doi:10.1093/annonc/mdz250 | v427

Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz250.054/5577557 by guest on 26 October 2019

Background: Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality. This study focused on identification of RNASeqexpressionsignature for prognosis prediction of Uterine Sarcoma. Methods: We obtained RNA-Seqexpression profiles from The Cancer Genome Atlas (TCGA) database and differential expressed genes (DEGs) were identified between US tissues and normal tissues. Univariate Cox proportional hazards regression analysis was performed to identify Prognosis associated DEGscorrelated with survival of US patients.The RNA-Seqbased prognostic signature was identified by least absolute shrinkage and selection operator (LASSO) Cox model. The cohort was randomly divided into training and testing groups. Thebiological pathway and processof putative RNA targets was also analyzed by bioinformatics. Results: This study identified a RNA-Seq signature based on 11 genes, AP000320.1, HNRNPA1P33, RPL21P10, AC067773.1, AC011933.3, STX19, AC091133.4, HIST1H3A, AC004988.1, AL356585.1 and HNRNPA3P1. In the training group, the median OS in the high-risk and low-risk groups were 13.7 vs 88.1 months (HR, 0.204, 95% CI, 0.08589 - 0.4846; P < 0.0001), respectively. In the testing group, the median OS in the high-risk and low-risk groups were 11.9 vs 67.2 months (HR, 0.04315, 95% CI, 0.004845 - 0.3842; P < 0.0001) respectively. Genes in the model were put into gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes signaling pathways analysis, which suggested that these genes might contribute to cancer-associated processes such as the nuclear nucleosome and DNA packaging complex. Conclusions: This 11-genebased prognostic signature may improve prognosis prediction of US. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Linguistic correction

1048P